Given the rapid emergence of resistance to monotherapy in cancer, we investigated whether combination BRD4i with WEE1 or ATR inhibition would be a strategy to exploit ARID1A loss by targeting two critical pathways critical for survival. Here, ARID1A is linked to cancer.